Who use statins and why? A cross-sectional analysis of statin utilisation in the context of cardiovascular risk and socio-demographic factors by Byrne, Paula et al.
References
1 HSE. Primary Care Reimbursement 
Service; Statistical Analysis of Claims and 
Payments 2013. 
2 Wallach Kildemoes H, Stovring H, Holme 
Hansen E, Howse K, Pétursson H. Statin 
prescribing according to gender, age and 
indication: what about the benefit–risk 
balance? Journal of Evaluation in Clinical 
Practice. 2015. 
3 Abramson, J. D., Rosenberg, H. G., Jewell, 
N. & Wright, J. M. 2013. Should people at low 
risk of cardiovascular disease take a statin? 
BMJ, 347, 6123. 
4 Goldacre, B. & Smeeth, L. 2014. Mass 
treatment with statins. BMJ, 349, 4745. 
5 Wu J, Zhu S, Yao GL, Mohammed MA, 
Marshall T. Patient factors influencing the 
prescribing of lipid lowering drugs for primary 
prevention of cardiovascular disease in UK 
general practice: a national retrospective 
cohort study. PLoS One. 2013;8(7):67611. 
WHO USE STATINS 
AND WHY?
A cross-sectional analysis of statin utilisation in the context of 
cardiovascular risk and socio-demographic factors from The Irish 
Longitudinal Study on Ageing (TILDA)
Background
Statins are widely prescribed for 
primary and secondary prevention 
of cardiovascular disease (CVD) and 
command a large share of drug 
expenditure. 1 The evidence base in 
various diagnostic categories varies, 
and therefore, so do the benefit-risk 
ratios. 2
Aim
To describe (i) the prevalence of statin 
utilisation by people aged over 50 and 
(ii) the factors associated with the 
likelihood of using a statin. 
Methods
Cross- sectional analysis of factors 
associated with statin utilisation from 
TILDA (n=5,618). Prevalence of statin 
utilisation was calculated according to 
age, gender and diagnosis. 
The likelihood of statin utilisation was 
estimated using multivariate logistic 
regression models.
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associated with statin utilisation 
(OR 3.53; CI 2.84 to 4.39), as were 
living with a spouse or partner and 
frequency of GP visits. 
Discussion
Given the on going debate on the 
appropriateness of statin use in 
primary prevention, 3 it is notable 
that a large proportion of Irish 
users fall into this category, 
particularly women. 4
The possible focus on hyperlipidae-
mia instead of overall CVD risk, as 
a reason for prescribing statins, may 
indicate an overemphasis on this 
single risk factor. 5
Polypharmacy, controlling for 
indication, was strongly associated 
with statin use. 
Conclusion
This study leads us to question if 
the widespread use of statins in 
some low- risk diagnostic categories 
represents the best use of scarce 
resources. 
There may be an over emphasis on 
single risk factors rather than 
overall risk of CVD. The association 
between polypharmacy and statin 
usage warrants further investigation. 
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their only reported CVD diagnosis 
were more likely to receive statins 
(OR 0.58, CI 0.40 to 0.83) 
than those with diabetes 
(OR 0.49, CI 0.32 to 0.75), 
potential atherosclerotic conditions 
(OR 0.27, CI 0.18 to 0.39) 
and hypertension (OR 0.28, CI 0.20 
to 0.40).  Reference category 
comprises those with myocardial 
infarction.
Results
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??? of women 
who are taking 
statins do so 
for primary 
prevention
????of those 
taking statins do 
so for primary 
prevention. 
??? of men 
who are taking 
statins do so 
for primary 
prevention.0
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